#USA #Class Action #New Orleans #ClaimsFiler #Capricor Therapeutics

Capricor Therapeutics Investors to File Lawsuit Claims

Investors who have purchased securities from Capricor Therapeutics, Inc. between December 17, 2025, and July 26, 2026, may have crucial legal options and need to act soon. ClaimsFiler, a free service designed to assist shareholders, reminds these investors that they have until September 28, 2026, to submit applications to become lead plaintiffs in an ongoing class action lawsuit. This action is being handled in the United States District Court for the Southern District of California and involves significant claims against the company.

The lawsuit arises from the allegation that Capricor and certain executives failed to disclose material information during the specified Class Period, which is a violation of federal securities laws. This allegation gained traction when the U.S. Food and Drug Administration (FDA) released documentation on July 27, 2026, revealing that Capricor made unauthorized alterations to its pre-specified statistical analysis plan ahead of the Biologics License Application (BLA) review of its lead product candidate, Deramiocel. These changes raised questions regarding the credibility and reliability of the data presented to regulators and led the FDA to view the company's analyses as potentially flawed.

The context deepened when the FDA pointed out that the changes Capricor made to convert raw changes to percent changes were unnecessary and scientifically unfounded, casting a shadow over the effectiveness of Deramiocel. As a direct consequence of these revelations, Capricor's stock plummeted by $12.70, equivalent to a staggering 64% drop, resulting in a closing share price of just $7.00 on July 27, 2026, amid extraordinary trading activity. The drastic sell-off indicates severe investor concern regarding the company's future and the integrity of its clinical data.

These developments underscore the importance of prompt action for shareholders who suffered losses in excess of $100,000. Those affected are encouraged to visit ClaimsFiler's website for further information on the case at ClaimsFiler.com or can directly contact them for assistance by calling 1-833-538-3604. Legal help is being provided by Kahn Swick & Foti, LLC, who are available to evaluate individual cases and discuss potential pathways forward.

For investors, understanding your rights in such situations is vital. The class action aims to hold Capricor accountable for its alleged transgressions, allowing affected shareholders to seek recompense for their financial losses. The firm's mission is to empower retail investors to reclaim their rightful share from the billions allocated in securities class action settlements. By registering at ClaimsFiler, investors can access essential information about similar cases, upload transactional data, and receive timely notifications on opportunities relevant to their financial interests.

As the deadline approaches, shareholders should prioritize their actions to ensure they do not miss their chance to be included in the proceedings as lead plaintiffs. Legal matters, particularly in the stock market, can be complex and require expedited decisions. Having knowledgeable legal counsel by one’s side can significantly alter the outcome of such serious cases as the one facing Capricor Therapeutics.